dermatology outlook: from the emotionally debilitating to the life-threatening The future of Allergan’s skin care business will be driven both by the continuing acceptance of TAZORAC and tazarotene oral in the marketplace as well as new prod- ucts flowing from our R&D pipeline. In the past few years, we have turned our sights on skin cancer as an indication that affects a growing number of people around the world yet is not adequately treated with currently avail- able therapeutics. Allergan has entered into a collaboration with Australia- based Peplin Biotech Ltd. for the development and commercialization of a topical treatment for non- melanoma skin cancer and actinic keratoses. The project is advancing Peplin’s lead candidate, PEP005, a plant- derived compound. In both pre-clinical studies and a small open-label human proof-of-principle clinical study, Peplin's technology has shown early promise in the treat- ment of a wide range of human cancers, with an initial emphasis on non-melanoma skin cancers.  An estimated 1.8 million new cases of non-melanoma skin cancer, which includes basal cell carcinoma and squamous cell carcinoma, are diagnosed each year in the United States alone. And the incidence of non-melanoma skin cancer is estimated to be increasing annually at approximately 6 to 7 percent.  The Peplin technology is an excellent addition to Allergan’s strong new product pipeline, and it has potential in the large, growing and under-served market for treat- ing non-melanoma skin cancer. Our strong R&D programs in dermatology underscore Allergan’s commitment to being a leader in specialty markets. Peplin Biotech Ltd. and Allergan are developing a topical treatment for non- melanoma skin cancer using PEP005, a compound derived from the Euphorbia peplusplant.